T 0545/12 (Anti-TNF antibodies and methotrexate/THE KENNEDY TRUST) of 14.06.2016
- European Case Law Identifier
- ECLI:EP:BA:2016:T054512.20160614
- Date of decision
- 14 June 2016
- Case number
- T 0545/12
- Petition for review of
- -
- Application number
- 97933799.5
- IPC class
- A61K 31/505A61K 39/395
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Anti-TNF antibodies / TNF receptor and methotrexate in the treatment of autoimmune disease
- Applicant name
- The Kennedy Trust for Rheumatology Research
- Opponent name
- Wyeth LLC (opposition withdrawn)
UCB, S.A. (opposition withdrawn)
AbbVie Inc.
Schering Corporation
Amgen Inc. - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 111(1)European Patent Convention Art 123(2)
- Keywords
- Transfer of opponent status (yes)
Main request: amendments - allowable (yes)
Remittal to the opposition division (yes) - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The request for transfer of the status as opponent from Abbott Laboratories to AbbVie Inc. is allowed.
2. The decision under appeal is set aside.
3. The case is remitted to the opposition division for further prosecution on the basis of the set of claims of the main request filed with the letter of 25 February 2013.